Mobicox

Concomitant administration of NSAIDs and SSRIs may increase the risk of gastrointestinal ulceration and bleeding. (See Warnings and Precautions, Gastrointestinal (GI).)

An interaction with oral hypoglycemic agents has been noted with some NSAIDs, however no interaction data is available for the co-administration of these agents with MOBICOX.

No drug interaction information is available for MOBICOX coadministered with oral contraceptives. A decrease of the efficacy of intrauterine devices by NSAIDs has been previously reported but needs further confirmation.

Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBICOX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering MOBICOX with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced. (See Warnings and Precautions, Hematologic, Anti-coagulants.)

Some studies have shown that the concomitant use of NSAIDs and oral glucocorticoids increases the risk of GI adverse events such as ulceration and bleeding via a synergistic effect. This is especially the case in older (>65 years of age) individuals.

Monitoring of plasma lithium concentrations is advised when stopping or starting a NSAID, as increased lithium concentrations can occur.

In clinical trials, NSAIDs have produced a reduction in renal lithium clearance and an elevation of plasma lithium levels, which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended. In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. These effects have been attributed to inhibition of renal prostaglandin synthesis by MOBICOX. If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.

Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. In vitro testing found no protein binding drug interaction between digoxin and meloxicam.

Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and C_max (24%) of meloxicam. The clinical significance of this interaction is not known.

The use of MOBICOX in addition to any other NSAID, including over-the-counter ones (such as ASA and ibuprofen) for analgesic and/or anti-inflammatory effect is not recommended because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions (e.g. increased risk of gastro-intestinal ulcers and bleeding).

The exception is the use of low dose ASA for cardiovascular protection, when another NSAID is being used for its analgesic/anti-inflammatory effect, keeping in mind that combination NSAID therapy is associated with additive adverse reactions. Concomitant administration of low-dose aspirin with MOBICOX may result in an increased rate of GI ulceration or other complications, compared to use of MOBICOX alone. MOBICOX is not a substitute for aspirin for cardiovascular prophylaxis.

Some NSAIDs (e.g. ibuprofen) may interfere with the antiplatelet effects of low dose ASA, possibly by competing with ASA for access to the active site of cyclooxygenase-1.

NSAIDs may diminish the anti-hypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.

Combinations of ACE inhibitors, angiotensin-II antagonists, diuretics and NSAIDs might have an increased risk for acute renal failure and hyperkalemia. Blood pressure and renal function (including electrolytes) should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.

NSAIDs and ACE Inhibitors or angiotensin-II receptor antagonists exert a synergistic effect on the decrease of glomerular filtration. In patients with pre-existing renal impairment this may lead to acute renal failure.

Meloxicam is eliminated almost entirely by hepatic metabolism, of which approximately two thirds are mediated by cytochrome (CYP) P450 enzymes (CYP 2C9 major pathway and CYP 3A4 minor pathway) and one-third by other pathways, such as peroxidase oxidation. The potential for a pharmacokinetic interaction should be taken into account when meloxicam and drugs known to inhibit, or to be metabolised by, CYP 2C9 and/or CYP 3A4 are administered concurrently.

Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. This resulted in a decrease in t_1/2, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.

Interactions with food have not been established.

Nephrotoxicity of cyclosporine or tacrolimus may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment with either of these drugs, renal function should be monitored.

Interactions with laboratory tests have not been established.

Interactions with herbal products have not been established.

A population kinetics study with MOBICOX indicated a lack of relevant interaction of sulfasalazine, gold compounds and glucocorticoids on the pharmacokinetics of MOBICOX. No drug interaction data is available for MOBICOX and the coadministration of the following products: phenytoin, acetaminophen, alcohol, aminoglycosides, butemide, colchicine, cyclosporin, indapamide, insulin, nephrotoxic agents, NSAIDs (other than ASA), oral contraceptives, potassium supplements, probenicid, valproic acid, zidovudine.

There are no specific studies about effects on the ability to drive vehicles and to use machinery. Patients who experience visual disturbances, drowsiness or other central nervous system disturbances should refrain from these activities.

Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. This effect has been attributed to inhibition of renal prostaglandin synthesis. Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Nevertheless, during concomitant therapy with furosemide and MOBICOX, patients should be observed closely for signs of declining renal function (see Warnings and Precautions, Renal), as well as to assure diuretic efficacy.

No pharmacokinetic interaction was detected with concomitant administration of antacids. MOBICOX tablets can be administered without regard to timing of antacids. (See Action and Clinical Pharmacology, Pharmacokinetics.)

A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. In vitro, methotrexate did not displace meloxicam from its human serum binding sites.

In case combination treatment with methotrexate and NSAIDs is necessary, blood cell count and the renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity. Although the pharmacokinetics of methotrexate (15 mg/week) were not relevantly affected by concomitant meloxicam treatment, it should be considered that the hematological toxicity of methotrexate can be amplified by treatment with NSAID drugs.

Concomitant administration of NSAIDs with a potentially myelotoxic drug, such as methotrexate, appears to be a predisposing factor to the onset of a cytopenia.

NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended. The risk of an interaction between NSAID preparations and methotrexate, should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function.

There is an increased risk of bleeding, via inhibition of platelet function, when anti-platelet agents, oral anti-coagulants, systemically administered heparin and thrombolytics are combined with NSAIDs, such as MOBICOX. If such co-prescribing cannot be avoided, close monitoring of the effects of anti-coagulants is required. (See Warnings and Precautions, Hematologic.)

Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.

No dose adjustment is necessary in patients with mild to moderate hepatic insufficiency.

No dose reduction is required in patients with clinically stable liver cirrhosis.

MOBICOX is contraindicated in patients with severe liver impairment or active liver disease.

See Contraindications; Warnings and Precautions, Hepatic/Biliary/Pancreatic and Action and Clinical Pharmacology, Special Populations and Conditions, Hepatic Insufficiency.

For elderly, frail or debilitated patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision.

See Contraindications; Warnings and Precautions, General and Special Populations, Geriatrics (>65 years of age) and Action and Clinical Pharmacology, Special Populations and Conditions, Geriatrics.

In patients with increased risks of adverse reactions, treatment should be started at the dose of 7.5 mg once daily.

The maximum recommended daily dose of MOBICOX (meloxicam) tablets is 15 mg.

Use of MOBICOX is restricted to adults 18 years of age and older and should be limited to the lowest effective dose for the shortest possible duration of treatment. (See Contraindications and Warnings and Precautions.)

7.5 mg once daily. If necessary, the dose may be increased to 15 mg once daily.

No dose reduction is required in patients with mild or moderate renal impairment (i.e., in patients with creatinine clearance of greater than 15 mL/min or 0.25 mL/s).

In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg/day.

MOBICOX is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min or 0.5 mL/sec) or deteriorating renal disease.

See Contraindications; Warnings and Precautions, Renal and Action And Clinical Pharmacology, Special Populations and Conditions, Renal Insufficiency.

15 mg once daily. According to the therapeutic response, the dose may be reduced to 7.5 mg once daily.

MOBICOX may be taken without regard to timing of meals.

If a dose is missed, the usual schedule must be resumed the following day. An extra dose must not be taken.

hepatitis, gastritis.

Additional reports of serious adverse events temporally associated with MOBICOX during worldwide post-marketing experience are included below. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or clearly establish a causal relationship to MOBICOX exposure.

Few patients in clinical trials in osteoarthritis (study 107.181) and rheumatoid arthritis (study 107.183) experienced abnormal hematologic or clinical chemistry findings with potential clinical significance. There were a few instances of decreased red blood cells in both meloxicam-treated (1.1%) and placebo-treated patients (0.7%). Increased red blood cells were experienced in placebo-treated patients (0.7%). Increased serum potassium was experienced in both meloxicam-treated patients (7.5 mg-0.7%, 15 mg-1.7%) and placebo-treated patients (1.3%). Increased blood urea nitrogen and increased serum creatinine was experienced in meloxicam-treated patients (1.3% and 2.0% respectively).

convulsions, dizziness, paresthesia, tremor, vertigo, tinnitus, drowsiness.

abnormal vision (including blurred vision), conjunctivitis, taste perversion, tinnitus.

alopecia, angioedema, bullous eruption, dermatitis bullous, photosensitivity reaction (photosensitisation), pruritus, sweating increased, stomatitis, urticaria.

The following serious adverse drug reactions have been reported in association with MOBICOX use:

• Gastrointestinal ulceration, perforation or bleeding (see Warnings and Precautions, Gastrointestinal (GI) and Drug Interactions, Drug-Drug Interactions, Selective Serotonin Reuptake Inhibitors (SSRIs);

  
  

• Asthma, bronchospasm (see Warnings and Precautions, Hypersensitivity Reactions, Anaphylactoid Reactions and Warnings and Precautions, Respiratory);

  
  

• Hypersensitivity reactions including angioedema, skin rash, pruritus (see Warnings and Precautions, Hypersensitivity Reactions, Anaphylactoid Reactions and Skin);

  
  

• Renal failure, hematuria (see Warnings and Precautions, Genitourinary and Renal, Drug Interactions, Drug-Drug Interactions, Anti-Hypertensives, Cyclosporine or Tacrolimus, Diuretics and Methotrexate);

  
  

• Visual disturbances including blurred vision (see Warnings and Precautions, Neurologic and Ophthalmologic);

  
  

• Vomiting or persistent dyspepsia, nausea, abdominal pain or diarrhea (see Warnings and Precautions, Gastrointestinal (GI) and Infection, Aseptic Meningitis);

  
  

• Micturition disorders;

  
  

• Oedema (see Warnings and Precautions, Cardiovascular and Renal, Fluid and Electrolyte Balance);

  
  

• Jaundice (see Warnings and Precautions, Hepatic/Biliary/Pancreatic);

  
  

• Malaise, fatigue;

  
  

• Aseptic meningitis (see Warnings and Precautions, Infection, Aseptic Meningitis);

  
  

• Confusion, depression, lightheadedness (see Warnings and Precautions, Neurologic);

  
  

• Tinnitus (see Warnings and Precautions, Neurologic).

allergic reaction, face edema, fatigue, fever, hot flushes, malaise, syncope, weight decrease, weight increase.

asthma, in individuals allergic to aspirin or other NSAIDs.

bullous reactions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Adverse Drug Reactions in a Placebo- and Active-controlled Trial in Rheumatoid Arthritis (107.183) with Incidence ≥1% in Any Treatment Displayed on Preferred Term Level

acute renal failure, interstitial nephritis, micturition disorders, acute urinary retention.

agranulocytosis.

angio-oedema and immediate hypersensitivity reactions, including anaphylactoid/anaphylactic reactions including shock.

conjunctivitis, visual disturbances including blurred vision.

jaundice, liver failure.

The information to compile the following data is based on clinical trials involving 14 325 patients who have been treated with daily oral doses of 7.5 and 15 mg MOBICOX tablets or capsules. In these clinical trials, the following indications were studied: osteoarthritis and rheumatoid arthritis (approved indications); ankylosing spondylitis, sciatica and low back pain (unapproved indications).

In the overall clinical trial database of 14 325 patients, treatment exposure up to 6 weeks was obtained in 14 313{*For 12 patients treated with meloxicam, information is missing to categorize the duration of exposure.} patients, while exposure up to 3 months was in 2185 patients. Exposure up to 6 months was in 1642 patients, exposure up to one year was obtained in 1031 patients and 471 patients were exposed for more than one year to meloxicam.

confusion and disorientation, alteration of mood.

The following is a list of adverse drug reactions regardless of causality occurring in <1% of patients receiving 7.5 or 15 mg MOBICOX in clinical trials involving approximately 14 325 patients. In these clinical trials, the following indications were studied: osteoarthritis and rheumatoid arthritis (approved indications); ankylosing spondylitis, sciatica and low back pain (unapproved indications).

albuminuria, abnormal renal function parameters (increased serum creatinine and/or serum urea), hematuria, acute renal failure.

dehydration.

abnormal dreaming, anxiety, appetite increased, confusion, depression, nervousness, somnolence.

The following adverse events, which may be causally related to the administration of MOBICOX, have a frequency of ≥1%.

angina pectoris, cardiac failure, hypertension (increase of blood pressure), hypotension, myocardial infarction, vasculitis, edema, flushes.

Heart Rate and Rhythm: arrhythmia, palpitation, tachycardia.

Safety and efficacy have not been established in the pediatric population. (See Contraindications.)

Evidence from clinical studies and postmarket experience suggests that use in the geriatric population is associated with differences in safety. (See Warnings and Precautions, Special Populations, Geriatrics (>65 years of age) and Dosage and Administration, Recommended Dose and Dosage Adjustment, Geriatrics (>65 years of age)).

Each round, biconvex, pastel yellow tablet, identified with “M” on one side and the company logo on the other side, contains: meloxicam 7.5 mg. Nonmedicinal ingredients: anhydrous colloidal silica, crospolyvidone, lactose, magnesium stearate, microcrystalline cellulose, polyvidone and sodium citrate. Bottles of 100 and 500.

Each round, pastel yellow, snap-tab tablet , impressed with the code “77C” on both sides of a broad score line on its concave side and the Boehringer company log on its convex side, contains: meloxicam 15 mg. Nonmedicinal ingredients: anhydrous colloidal silica, crospolyvidone, lactose, magnesium stearate, microcrystalline cellulose, polyvidone and sodium citrate. Bottles of 100 and 500.

Long-term administration of NSAIDs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis, hematuria, low grade proteinuria, glomerulonephritis, renal medullary necrosis and occasionally nephrotic syndrome.

Renal insufficiency due to NSAID use is seen in patients with pre-renal conditions leading to reduction in renal blood flow or blood volume. Under these circumstances, renal prostaglandins help maintain renal perfusion and glomerular filtration rate (GFR). In these patients, administration of a NSAID may cause a reduction in prostaglandin synthesis leading to impaired renal function. Patients at greatest risk of this reaction are those with pre-existing renal insufficiency (GFR <60 mL/min or 1 mL/s), dehydrated patients, patients on salt restricted diets, those with congestive heart failure, cirrhosis, liver dysfunction, taking angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, cyclosporine, diuretics and those who are elderly. Serious or life-threatening renal failure has been reported in patients with normal or impaired renal function after short-term therapy with NSAIDs. Even patients at risk who demonstrate the ability to tolerate a NSAID under stable conditions may decompensate during periods of added stress (e.g. dehydration due to gastroenteritis). Discontinuation of NSAIDs is usually followed by recovery to the pre-treatment state.

The extent to which metabolites may accumulate in patients with renal failure has not been studied with MOBICOX. As with other NSAIDs, metabolites of which are excreted by the kidney, patients with significantly impaired renal function should be more closely monitored.

Caution should be used when initiating treatment with NSAIDs, such as MOBICOX, in patients with considerable dehydration. Such patients should be rehydrated prior to initiation of therapy. Caution is also recommended in patients with pre-existing kidney disease. No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 15 mL/min or 0.25 mL/s).

See Contraindications, Coronary Artery Bypass Graft Surgery.

Numerous studies have shown that the concomitant use of NSAIDs and anti-coagulants increases the risk of bleeding. Concurrent therapy of MOBICOX with warfarin requires close monitoring of the international normalized ratio (INR).

Even with therapeutic INR monitoring, increased bleeding may occur. (See Drug Interactions, Drug-Drug Interactions, Anti-coagulants.)

MOBICOX (meloxicam) is not a substitute for corticosteroids. It does not treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. (See Drug Interactions, Drug-Drug Interactions, Glucocorticoids.)

ASA-induced asthma is an uncommon but very important indication of ASA and NSAID sensitivity. It occurs more frequently in patients with asthma who have nasal polyps.

Blurred and/or diminished vision has been reported with the use of NSAIDs. If such symptoms develop MOBICOX should be discontinued and an ophthalmologic examination performed. Ophthalmologic examination should be carried out at periodic intervals in any patient receiving MOBICOX for an extended period of time.

MOBICOX is contraindicated in for use during pregnancy. The risks during the third trimester are premature closure of the ductus arteriosus and prolonged parturition.

Inhibition of prostaglandin-synthesis may adversely affect pregnancy and/or the embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy.

In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

During the third trimester of pregnancy all prostaglandin-synthesis inhibitors may expose the foetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labour.

See Contraindications.

As with other NSAIDs, borderline elevations of one or more liver enzyme tests (AST, ALT, alkaline phosphatase) may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs.

A patient with signs and/or symptoms suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with MOBICOX. Severe hepatic reactions including jaundice and cases of fatal hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported with NSAIDs.

Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop (e.g. jaundice), or if systemic manifestations occur (e.g., eosinophilia, associated with rash, etc.), MOBICOX should be discontinued.

If there is a need to prescribe MOBICOX in the presence of impaired liver function, it must be done under strict observation.

Patients older than 65 years (hereafter referred to as older or elderly) and frail or debilitated patients are more susceptible to a variety of adverse reactions from NSAIDs. The incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. Most reports of fatal GI events are in this population. Older patients are also at risk of a lower esophageal injury including ulceration and bleeding. For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision.

Some NSAIDs are associated with persistent urinary symptoms (bladder pain, dysuria, urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with a NSAID.

Should urinary symptoms occur, in the absence of an alternate explanation, treatment with MOBICOX should be stopped to ascertain if symptoms disappear. This should be done before any urological investigations or treatments are carried out.

Some patients may experience drowsiness, dizziness, blurred vision, vertigo, tinnitus, hearing loss, insomnia or depression with the use of NSAIDs, such as MOBICOX. If patients experience these side effects, they should exercise caution in carrying out activities that require alertness.

For relevant drug interactions that require particular attention, see Drug Interactions.

Frail or debilitated patients may tolerate side effects less well and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible duration. As with other NSAIDs, caution should be used in the treatment of elderly patients who are more likely to be suffering from impaired renal, hepatic or cardiac function. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.

MOBICOX is not recommended for use with other NSAIDs, with the exception of low-dose ASA for cardiovascular prophylaxis, because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions. (See Drug Interactions, Drug/Drug Interactions, Acetylsalicylic Acid (ASA) or Other NSAIDs.)

MOBICOX tablets 7.5 mg contains 47 mg lactose per maximum recommended daily dose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.

MOBICOX tablets 15 mg contains 20 mg lactose per maximum recommended daily dose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Serious GI toxicity (sometimes fatal), such as peptic/duodenal ulceration, inflammation, perforation, obstruction and gastrointestinal bleeding, can occur at any time, with or without warning symptoms in patients treated with NSAIDs, such as MOBICOX. Minor upper GI problems, such as dyspepsia, commonly occur at any time. Health care providers should remain alert for ulceration and bleeding in patients treated with MOBICOX, even in the absence of previous GI tract symptoms. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. (See Warnings and Precautions, Special Populations, Geriatrics (>65 years of age).)

Patients should be informed about the signs and/or symptoms of serious GI toxicity and instructed to discontinue using MOBICOX and seek emergency medical attention if they experience any such symptoms. The utility of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed. Most patients who develop a serious upper GI adverse event on NSAID therapy have no symptoms. Upper GI ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue, thus increasing the likelihood of developing a serious GI event at some time during the course of therapy. Even short-term therapy has its risks.

Caution should be taken if prescribing MOBICOX to patients with a prior history of peptic/duodenal ulcer disease or gastrointestinal bleeding as these individuals have a greater than 10-fold higher risk for developing a GI bleed when taking a NSAID than patients with neither of these risk factors. Other risk factors for GI ulceration and bleeding include the following: H. pylori infection, increased age, prolonged use of NSAID therapy, excess alcohol intake, smoking, poor general health status or concomitant therapy with any of the following: anti-coagulants (e.g. warfarin); antiplatelet agent (e.g. ASA, clopidogrel); oral corticosteroids (e.g. prednisone); Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. citalopram, fluoxetine, paroxetine, sertraline).

Prospective, long-term studies required to compare the incidence of serious clinically significant upper gastrointestinal adverse events among patients taking meloxicam versus other NSAID products have not been performed.

There is no definitive evidence that the concomitant administration of histamine H₂ receptor antagonists and/or antacids will either prevent the occurrence of gastrointestinal adverse events or allow continuation of therapy when and if these adverse reactions appear.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike acetylsalicylic acid (ASA) their effect on platelet function is quantitatively less, or of shorter duration, and reversible.

MOBICOX and other NSAIDs have no proven efficacy as anti-platelet agents and should not be used as a substitute for ASA or other anti-platelet agents for prophylaxis of cardiovascular thromboembolic diseases. Anti-platelet therapies (e.g. ASA) should not be discontinued. There is some evidence that use of NSAIDs with ASA can markedly attenuate the cardioprotective effects of ASA. (See Drug Interactions, Drug-Drug Interactions, Acetylsalicylic Acid (ASA) or Other NSAIDs.)

Concomitant administration of MOBICOX with low dose ASA increases the risk of GI ulceration and associated complications.

For information on interaction between low dose ASA and MOBICOX and any other interaction, see Drug Interactions, Acetylsalicylic Acid (ASA) or Other NSAIDs.

See Contraindications.

Safety and effectiveness of MOBICOX in pediatric patients below the age of 18 years have not been evaluated.

The use of MOBICOX, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.

Use of NSAIDs, such as MOBICOX, can promote sodium retention in a dose-dependent manner, which can lead to fluid retention and edema, and consequences of increased blood pressure and exacerbation of congestive heart failure. Thus, caution should be exercised in prescribing MOBICOX in patients with a history of congestive heart failure, compromised cardiac function, hypertension, increased age or other conditions predisposing to fluid retention. For patients at risk, clinical monitoring is recommended. (See Warnings and Precautions, Cardiovascular.)

Use of NSAIDs, such as MOBICOX, can increase the risk of hyperkalemia, especially in patients with diabetes mellitus, renal failure, increased age, or those receiving concomitant therapy with adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, cyclosporine, or some diuretics.

Electrolytes should be monitored periodically. (See Contraindications.)

MOBICOX should not be given to patients with complete or partial syndrome of ASA-intolerance (rhinosinusitis, urticaria/angioedema, nasal polyps, asthma) in whom asthma, anaphylaxis, urticaria/angioedema, rhinitis or other allergic manifestations are precipitated by ASA or other NSAIDs. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at risk of a severe fatal reaction even if they have taken NSAIDs in the past without any adverse reaction. (See Contraindications.)

Patients sensitive to any one of the NSAIDs may be sensitive to any of the other NSAIDs as well.

MOBICOX, in common with other NSAIDs, may mask signs and symptoms of an underlying infectious disease.

See Warnings and Precautions, Neurologic.

As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to MOBICOX. In post-marketing experience, rare cases of anaphylactic/anaphylactoid reactions and angioedema have been reported in patients receiving MOBICOX. MOBICOX should not be given to patients with the ASA-triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking ASA or other NSAIDs (see Contraindications). Emergency help should be sought in cases where anaphylactoid reaction occurs.

NSAIDs inhibiting prostaglandin biosynthesis interfere with platelet function to varying degrees; patients who may be adversely affected by such an action, such as those on anti-coagulants or suffering from hemophilia or platelet disorders should be carefully observed when MOBICOX is administered.

See Contraindications.

See Warnings and Precautions, Skin.

Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anemia, and agranulocytosis) associated with the use of NSAIDs are rare, but can occur with severe consequences.

Anemia is sometimes seen in patients receiving NSAIDs, including MOBICOX. This may be due to fluid retention, GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including MOBICOX, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss.

The incidence of treatment-related anemia is more frequent than 1%. The incidence of disturbances of blood count, including differential white cell count, leukopenia and thrombocytopenia, is between 0.1 and 1%.

Concomitant administration of a potentially myelotoxic drug, in particular methotrexate, appears to be a predisposing factor to the onset of a cytopenia.

See Warnings and Precautions, Infection, Aseptic Meningitis.

The following monitoring criteria and laboratory tests are recommended for patients taking MOBICOX. This is not an exhaustive list.

Laboratory Testing:

• Potassium (Renal function, Hyperkalemia)

  
  

• INR/effects of anti-coagulants (co-prescription of oral anti-coagulants)

  
  

• Serum transaminases and other liver function tests (liver function)

  
  

• Renal function parameters such as serum creatinine and serum urea (in case of Methotrexate, Diuretics, Cyclosporine, ACE-Inhibitor or ARB co-prescription, and in susceptible patients re: the renal effects of meloxicam, e.g. impaired renal function or dehydration)

  
  

• Lithium plasma concentrations (in case of Lithium co-prescription)

  
  

• Blood cell count, including differential white cell count (in case of Methotrexate co-prescription)

  
  

Monitoring Activities:

• Patients with GI symptoms

  
  

• Patients with oral anticoagulation (see above)

  
  

• Blood pressure (in case of Anti-hypertensives co-prescription, and in susceptible patients with fluid retention)

  
  

• Periodic ophthalmologic evaluation (in patients on extended treatment).

  
  

For more information, please refer to the Warnings and Precautions and Drug Interactions.

Rarely, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissues diseases, etc.) seem to be pre-disposed. Therefore, in such patients, the health care provider must be vigilant to the development of this complication.

In rare cases, serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis and erythema multiforme have been associated with the use of some NSAIDs. Because the rate of these reactions is low, they have usually been noted during post-marketing surveillance in patients taking other medications also associated with the potential development of these serious skin reactions. Thus, causality is not clear. These reactions are potentially life threatening but may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. MOBICOX should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Patients should be advised that if they experience a skin rash they should discontinue their NSAID and contact their physician for assessment and advice, including which additional therapies to discontinue.

MOBICOX is contraindicated in nursing women.

MOBICOX is contraindicated for use in women who are breastfeeding because of the potential for serious adverse reactions in nursing infants. NSAIDs are known to pass into mother’s milk.

MOBICOX is a non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. The risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

Caution should be exercised in prescribing MOBICOX to patients with risk factors for cardiovascular disease, cerebrovascular disease or renal disease, such as any of the following (not an exhaustive list): hypertension; dyslipidemia/hyperlipidemia; diabetes mellitus; congestive heart failure (NYHA I); coronary artery disease (atherosclerosis); peripheral arterial disease; smoking; creatinine clearance (<60 mL/min or 1 mL/sec).

Use of NSAIDs, such as MOBICOX, can lead to new hypertension or can worsen pre-existing hypertension, either of which may increase the risk of cardiovascular events as described above. Thus blood pressure should be monitored regularly. Consideration should be given to discontinuing MOBICOX should hypertension either develop or worsen with its use.

Use of NSAIDs, such as MOBICOX, can induce fluid retention and edema, and may exacerbate congestive heart failure, through a renally-mediated mechanism. (See Warnings and Precautions, Renal, Fluid and Electrolyte Balance.)

For patients with a high risk of developing an adverse CV event, other management strategies that do not include the use of NSAIDs should be considered first. To minimize the potential risk for an adverse CV event, the lowest effective dose should be used for the shortest possible duration.

Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in subjects with mild (Child-Pugh Class I) and moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic insufficiency. No dose adjustment is necessary in mild to moderate hepatic insufficiency. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied.

Elderly males (≥65 years of age) exhibited meloxicam plasma concentrations and steady state pharmacokinetics similar to young males. Elderly females (≥65 years of age) had a 47% higher AUC_ss and 32% higher C_{max ss} as compared to younger females (<55 years of age) after body weight normalization. Despite the increased total concentrations in the elderly females, the adverse event profile was comparable for both elderly patient populations. A smaller free fraction was found in elderly female patients in comparison to elderly male patients.

Mean plasma clearance at steady state in elderly subjects was slightly lower than that reported for younger subjects.

The mean volume of distribution (Vss) of meloxicam is approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to ~99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam.

Meloxicam concentrations in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in animals. Meloxicam showed potent anti-inflammatory activity in all standard models of inflammation. NSAIDs are believed to exert their pharmacologic effects primarily through inhibition of the enzyme cyclooxygenase (COX). In turn, inhibition of this enzyme leads to an inhibition of biosynthesis of prostaglandins and other autacoids, substances which are potent biological mediators involved in diverse physiologic functions as well as pathologic conditions.

To date, two isozymes of COX have been identified and characterized, namely, COX-1 and COX-2 which have different intrinsic properties, expression controls and localization. COX-1, the constitutive form, has been described as a constitutive enzyme occurring in many tissues including the gastrointestinal tract, kidney, lungs, brain and platelets. COX-1 is found in blood vessels, platelets, stomach and kidney. In contrast, COX-2, the inducible form, is mostly an inducible enzyme, limited in distribution and expressed in high levels in inflamed tissues. COX-2 is thought to be involved in inflammatory responses. Recent studies have shown that differential inhibition of these two isozymes is associated with a different biological profile. Meloxicam has shown a selective inhibition of COX-2 in several in vitro test systems, as demonstrated by a greater dose dependent inhibition of COX-2 over COX-1 at levels similar to those seen in plasma at therapeutic steady state concentrations. The prostaglandins produced by the cyclooxygenases are not the only factors involved in the protection of the gastric mucosa.

A human pharmacology study compared the effects of meloxicam 7.5 mg once daily and indomethacin 25 mg three times daily on platelet aggregation and platelet thromboxane formation, which are exclusively COX-1 dependent, and renal prostaglandin (PGE₂) excretion. Platelet aggregation and thromboxane formation were almost completely inhibited by indomethacin but remained unaffected by meloxicam. Meloxicam showed no significant effects on urinary PGE₂ excretion whereas indomethacin reduced urinary PGE₂ excretion by 43%.

In another study, meloxicam (7.5 and 15 mg) demonstrated a greater inhibition of COX-2 ex vivo, as demonstrated by a greater inhibition of lipopolysaccharide-stimulated PGE₂ production (COX-2) as compared with serum thromboxane production (COX-1).

Meloxicam has been shown to inhibit COX-2 in several in vitro and ex vivo test systems. The inhibition of thromboxane in platelets, and consequently platelet aggregation, occurs via inhibition of COX-1. Meloxicam inhibition of thromboxane in platelets (via COX-1) is dose dependent and incomplete at anti-inflammatory doses. No significant inhibition of platelet aggregation has been observed with meloxicam at the recommended therapeutic doses of 7.5 and 15 mg once daily.

Inhibition of COX-2 also inhibits the production of systemic prostacyclin. Inhibition of prostacyclin may have a pro-thrombotic effect.

Prospective, controlled, long-term (>3 months) studies required to establish the clinical significance of these results have not been performed.

Pharmacokinetic data in Japanese subjects suggest a lower clearance of meloxicam in comparison to Caucasian subjects, but is not considered to require dose-adjustment due to the high intra-individual variability observed.

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%.

The mean elimination half-life (t_1/2) ranges from 15 hours to 20 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.

Meloxicam pharmacokinetics have been investigated in subjects with different degrees of renal insufficiency. Total drug plasma concentrations decreased with the degree of renal impairment while free AUC values were similar. Total clearance of meloxicam increased in these patients probably due to the increase in free fraction leading to an increased metabolic clearance. There is no need for dose adjustment in patients with mild to moderate renal failure (CrCL >15 mL/min or >0.25 mL/s). Patients with severe renal insufficiency have not been adequately studied. The use of MOBICOX in subjects with severe renal impairment is not recommended (see Warnings and Precautions, Advanced Renal Disease).

In terminal renal failure, the increase in the volume of distribution may result in higher free meloxicam concentrations, and a daily dose of 7.5 mg must not be exceeded.

Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg MOBICOX, the mean elimination half-life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the data were similar (17.9 hours vs 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the C_max or T_max across genders.

Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. The major metabolite, 5'-carboxy meloxicam (60% of dose), from P450 mediated metabolism was formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of dose). In vitro studies indicate that cytochrome P450 2C9 plays an important role in this metabolic pathway with a minor contribution of the CYP 3A4 isozyme. Patients' peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively.

Drug intake after a high fat breakfast (75 g of fat) did not affect extent of absorption of meloxicam capsules, but led to 22% higher C_max values. Mean C_max values were achieved between five and six hours. No pharmacokinetic interaction was detected with concomitant administration of antacids. MOBICOX tablets can be administered without regard to timing of meals and antacids.

Following a single dose of meloxicam, the free C_max plasma concentrations were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable.

See Action and Clinical Pharmacology, Mechanism of Action.

In a study of 36 children, kinetic measurements were made in 18 children at doses of 0.25 mg/kg BW. Maximum plasma concentration C_max (−34%) as well as AUC0_0-∞ (−28%) tended to be lower in the younger age group (aged 2 to 6 years, n=7) as compared to the older age group (7 to 14 years, n=11) while weight normalized clearance appeared to be higher in the younger age group. A historical comparison with adults revealed that plasma concentrations were at least similar for older children and adults. Plasma elimination half-lives (13 h) were similar for both groups and tended to be shorter than in adults (15-20 h).

Single Dose and Steady-state Pharmacokinetic Parameters for Oral 15 mg Meloxicam (Mean and % CV)^a